OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM
Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference
Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer
Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results
Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction
Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results
Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
Two Biotechs Are Set to Start Trading Today
Reneo Pharmaceuticals Announces Pricing of Initial Public Offering